Summary: Bio-Techne Corporation

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • The company's MSCI ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Highlights: Bio-Techne Corporation

  • The earnings growth currently anticipated by analysts for the coming years is particularly strong.
  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.

Weaknesses: Bio-Techne Corporation

  • The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 61.68 times its estimated earnings per share for the ongoing year.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • The company is highly valued given the cash flows generated by its activity.
  • The company is not the most generous with respect to shareholders' compensation.
  • Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings Chart: Bio-Techne Corporation

Source: Surperformance

ESG chart: Bio-Techne Corporation

Source: MSCI

Add to a list
Fundamentals Valuation Revisions of Fundamental Estimates Capi.($)
11.92B
48.93B
38.11B
26.56B
16.18B
15.79B
11.19B
9.17B
Average 22.23B
Weighted average by Cap.
See all sector ratings
Investor
Trader
ESG MSCI
A

Financials

Sales growth
EPS Growth
Profitability
Net margin
Financial Health

Valuation

P/E ratio
EV/REVENUE
EV/EBITDA
PBR
Yield

Revisions

1 year Revenue revision
4 months Revenue revision
1 months Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analysts' recommendations
4m Revision of opinion
Potential Price Target
4m Target Price Revision
12m Target Price Revision

Business Predictability

Earnings quality
Analyst Coverag
Divergence of analysts' recommendations
Divergence of Target Price
Divergence of analysts' opinions

ESG

Environment
Social
Governance
Controversy
ESG: Ethical controversies
ESG: Human rights controversies
ESG: Tax subsidies controversies
Sharia compliant
-

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. TECH Stock
  4. Ratings Bio-Techne Corporation